Identification of Imipenem-Resistant Genes in Acinetobacter baumannii Isolated from Baghdad HospitalsNadheema Hammood Hussein1, Harith Jabbar Fahad Al-Mathkhury2* and Majeed Arsheed Sabbah3
- *Corresponding Author:
- Harith Jabbar Fahad Al-Mathkhury
Department of Biology, College of Science
University of Baghdad, Iraq
E-mail: [email protected]
Received date: September 05, 2014; Accepted date: November 20, 2014; Published date: November 22, 2014
Citation: Hussein NH, Al-Mathkhury HJF, Sabbah MA (2014) Identification of Imipenem-Resistant genes in Acinetobacter baumannii Isolated from Baghdad Hospitals. J Med Microb Diagn 3:170. doi:10.4172/2161-0703.1000170
Copyright: © 2014 Hussein NH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Imipenem-resistant Acinetobacter baumannii (IRAB) represents one of the important causing agents of nosocomial infections especially in immunocompromised and Intensive Care Units (ICUs) patients. The aim of this work was to identify the Imipenem-Resistant genes in Acinetobacter baumannii isolated from Baghdad hospitals. Among 128 A. baumannii isolates, 67 isolates (58.26%) were resistant to imipenem and meropenem. Four genes for imipenem resistance (blaOXA-23 like, blaOXA-24 like, blaOXA-51like and blaOXA-58 like) were amplified and sequenced. The presence of blaOXA-23-like genes in 91.03% of IRAB isolates indicated that the blaOXA-23-like genes are the predominant mechanism for imipenem resistance in our isolates. Sequencing of PCR products showed the presence of new OXA-genes in local A. baumannii isolates including: OXA-207, OXA-239 and OXA-229 among the genes of OXA-24-like, OXA-23-like and OXA-58-like genes, respectively. In conclusion, this study identifies the genes responsible for the imipenem resistance in Baghdad which is important to understand the imipenem resistance and to suggest plans for treatment of patients in future.